Literature DB >> 32164586

Lipid profile and risk of ovarian tumours: a meta-analysis.

Justina Ucheojor Onwuka1, Akinkunmi Paul Okekunle2,3,4, Olaniyi Matthew Olutola5, Onoja Matthew Akpa5,6, Rennan Feng7.   

Abstract

BACKGROUND: Existing data from several reports on the association between lipid profile and ovarian tumour (OT) suggests divergent conclusions. Our aim was to examine whether circulating lipid profile: total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) differed between cases and non-cases of OT.
METHODS: Electronic repositories; PUBMED, EMBASE and Cochrane library were explored through December 2019 to retrieve published articles for inclusion in the meta-analysis after quality assessment. Heterogeneity was assessed using I2 statistics, the effect of individual studies on the overall effect size was tested using sensitivity analysis and funnel plot was used to evaluate publication bias.
RESULTS: Twelve studies, involving 1767 OT cases and 229,167 non-cases of OT were included in this meta-analysis and I2 statistics ranged between 97 and 99%. Mean circulating TC (- 16.60 [- 32.43, - 0.77]mg/dL; P = 0.04) and HDL (- 0.25[- 0.43, - 0.08]mmol/L; P = 0.005) were significantly lower among OT cases compared to non-OT cases.
CONCLUSION: Decreased TC and HDL profiles were observed among subjects with OT in this collection of reports. The implications of TC and HDL in tumour manifestations and growth need to be validated in a large multi-ethnic longitudinal cohort adjusting for relevant confounders.

Entities:  

Keywords:  High-density lipoprotein; Lipid profile; Low-density lipo-protein; Ovarian tumour; Total cholesterol; Triglyceride

Year:  2020        PMID: 32164586     DOI: 10.1186/s12885-020-6679-9

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  6 in total

1.  The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms.

Authors:  Li Quan; Yongkang Liu; Wenjing Cui; Xinru Wang; Weixiao Zhang; Zhongqiu Wang; Chuangen Guo; Chao Lu; Feixiang Hu; Xiao Chen
Journal:  Lipids Health Dis       Date:  2022-07-16       Impact factor: 4.315

Review 2.  Influence of cholesterol on cancer progression and therapy.

Authors:  Shyamananda Singh Mayengbam; Abhijeet Singh; Ajay D Pillai; Manoj Kumar Bhat
Journal:  Transl Oncol       Date:  2021-03-19       Impact factor: 4.243

Review 3.  Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.

Authors:  Chang-Feng Deng; Neng Zhu; Tan-Jun Zhao; Hong-Fang Li; Jia Gu; Duan-Fang Liao; Li Qin
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

4.  Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer.

Authors:  Yusuke Kobayashi; Takashi Takeda; Haruko Kunitomi; Fumiko Chiwaki; Masayuki Komatsu; Shimpei Nagai; Yuya Nogami; Kosuke Tsuji; Kenta Masuda; Hideaki Ogiwara; Hiroki Sasaki; Kouji Banno; Daisuke Aoki
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-21

5.  Association of lipid profile with obesity among breast cancer survivors: a cross-sectional study.

Authors:  Akinkunmi Paul Okekunle; Ga-Eun Yie; Sihan Song; Zisun Kim; Hyun Jo Youn; Jihyoung Cho; Jun Won Min; Yoo Seok Kim; Jung Eun Lee
Journal:  Lipids Health Dis       Date:  2022-08-02       Impact factor: 4.315

6.  Low blood levels of high-density lipoprotein (HDL) cholesterol are positively associated with cancer.

Authors:  Sven H Loosen; Karel Kostev; Tom Luedde; Christoph Roderburg; Mark Luedde
Journal:  J Cancer Res Clin Oncol       Date:  2021-12-12       Impact factor: 4.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.